GlassScriptPhysician profile
Stephani D Carver
NPI 1083207211
$3,650.38
in general payments reported to CMS, 2019-2025
28 companies · $563 in 2025
The $563 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,163 · 2022: $486 · 2023: $409 · 2024: $1,029 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,248.35 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $432.77 | 2024-2025 | Zenpep, Vowst |
| Novo Nordisk INC | $285.16 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.91 | 2023-2025 | Entyvio, Eohilia |
| Esperion Therapeutics, INC. | $165.76 | 2021 | |
| Phathom Pharmaceuticals, INC. | $163.58 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $156.30 | 2021-2022 | |
| Lilly USA, LLC | $140.77 | 2021-2024 | Omvoh |
| Janssen Biotech, INC. | $137.19 | 2023-2025 | Stelara, Simponi Aria, Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.75 | 2021-2022 | |
| Lucid Diagnostics INC. | $87.57 | 2024 | |
| Merck Sharp & Dohme LLC | $77.23 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $56.04 | 2023-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $42.43 | 2023 | |
| Intercept Pharmaceuticals, INC. | $40.88 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $34.15 | 2024 | Qsymia |
| Pfizer INC. | $31.14 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.88 | 2022 | |
| Boston Scientific Corporation | $30.26 | 2024 | Watchman Flx |
| Genzyme Corporation | $28.52 | 2024 | |
| Alnylam Pharmaceuticals INC. | $24.57 | 2024 | Givlaari |
| Amarin Pharma, INC. | $21.22 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $20.84 | 2025 | Iqirvo |
| Exact Sciences Corporation | $19.61 | 2024 | Cologuard Collection Kit |
| Eisai INC. | $17.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.03 | 2023 | Plenvu, Xifaxan |
| Insulet Corporation | $14.42 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephani Carver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.